Clinical Trial Update: Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone Metastases [Phase 1, Phase 2]

View source ↗

Summary

This Phase 1/2 trial update assesses the safety of re-treatment with Radium-223 dichloride in men with metastatic castration-resistant prostate cancer with bone…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Xofigo (radium-223 dichloride)

Snippet

Sponsor: Bayer | Conditions: Prostatic Neoplasms | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2016-09-29